ALPHARETTA, Ga., March 29, 2007 /PRNewswire/ -- Alliant Pharmaceuticals announced today survey results showing that children prefer Orapred ODT(TM) (Prednisolone sodium phosphate orally disintegrating tablets) over liquid steroids.(1)
The results of the patient feedback survey involving more than 900 children (n=973), showed that 89% (n=870) of the children preferred Orapred ODT over liquid versions. The results also showed that 83% (n=809) of the respondents liked the taste of Orapred ODT, and 97% (n=942) said Orapred ODT was easy to take. In addition, 96% (n=937) of the patients reported that they were able to take all of their medication as prescribed.
Orapred ODT is the first orally disintegrating tablet form of prednisolone available in the United States. Orapred ODT is prescribed primarily for acute exacerbations of asthma in children. It is also used to control severe, persistent asthma and to reduce inflammation seen in numerous medical conditions including arthritis and cancer. The indication and important safety information for Orapred ODT is listed below.
"Orapred ODT's exclusive taste-masking technology helps disguise prednisolone's typically bitter taste," said Mark Pugh, President of Alliant Pharmaceuticals. "We are pleased to see that, based on these results; patients appreciate both the taste and convenience that Orapred ODT has to offer."
Orapred ODT utilizes a proprietary orally disintegrating tablet technology to provide a taste-masked, non refrigerated and convenient formulation of prednisolone.
Alliant Pharmaceuticals sponsored the survey that was initiated in September, 2006 and ran until December 2006. Patients were included in the multi-center survey if they required steroid burst therapy for asthma exacerbation and were required to have taken a liquid steroid in the past. Physicians were instr ucted to prescribe Orapred ODT according to NHLBI dosing guidelines of 1-2 mg per kg in single or divided doses. Patients were asked to respond to questions regarding taste, ease of use, preference over liquid steroid, and ability to take all medication as prescribed.
Important Safety Information
Orapred ODT(TM) (Prednisolone sodium phosphate orally disintegrating tablets) is a prescription drug product indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with asthma or asthma caused by respiratory disorders. Orapred is contraindicated in patients with systemic fungal infections. Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered; however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease. Orapred may cause mood swings. Adverse effects of Orapred include the following: endocrine (including development of cushingoid state, increased requirements for insulin or oral hypoglycemic agents in diabetic patients, manifestations of latent diabetes mellitus); fluid and electrolyte disturbances (including fluid retention, hypertension); gastrointestinal (including peptic ulcer with possible perforation and hemorrhage); increased appetite; and weight gain.
For additional safety information, please see full prescribing information available online at: http://www.orapredodt.com
Reference: 1. Patient Feedback Survey. Data on file as of 03/23/07. Alliant Pharmaceuticals, Inc.
About Alliant Pharmaceuticals, Inc.
Alliant Pharmaceuticals, Inc. is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products to pediatricians and pediatric specialty physicians. Alliant Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. Additional information about Alliant Pharmaceuticals in available online at: http://www.alliantpharma.com.
Media Contact: Sharon Kraun
Cohn, Overstreet & Parrish
CONTACT: Sharon Kraun of Cohn, Overstreet & Parrish, +1-404-961-2242,, for Alliant Pharmaceuticals, Inc. firstname.lastname@example.org
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company